Mesoblast To Issue 10.2 Million Shares to Osiris Therapeutics Following US FDA Approval of Cell Treatment; Shares Fall 6%
Mesoblast To Issue 10.2 Million Shares to Osiris Therapeutics Following US FDA Approval of Cell Treatment; Shares Fall 6%
Mesoblast將向Osiris Therapeutics發行1020萬股股份，此舉是在美國FDA批准電芯治療後；股價下跌6%
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間